Market Segmentation:
- By Disorder Type
- Autistic Disorder
- Asperger Syndrome
- Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
- Childhood Disintegrative Disorder
- Rett Syndrome
- By Treatment Type
- Behavioral Therapy
- Speech and Language Therapy
- Occupational Therapy
- Pharmacological Treatment
- Complementary and Alternative Therapies
- Others (Nutritional Therapy, Sensory Integration Therapy)
- By End-User
- Hospitals and Clinics
- Rehabilitation Centers
- Therapeutic Centers
- Others (Home Care Settings, Educational Institutions)
- By Age Group
- Children (0-12 years)
- Adolescents (13-17 years)
- Adults (18 years and above)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Direct Procurement from Manufacturers)
- By Product Type
- Drugs
- Devices
- Services
- By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The Autism Spectrum Disorder Market had an estimated market size worth US$ 6.2 billion in 2023.
Rising prevalence of ASD, increasing awareness and screening, government support and funding, demand for effective therapies, advancements in diagnostics and treatment, growing healthcare expenditure, and increasing research and development efforts.
High treatment costs, lack of trained professionals, social stigma and misconceptions, regulatory challenges for approvals, limited access to care in some regions, and the complexity of the disorder.
The autistic disorder segment is the leading component segment in the Autism Spectrum Disorder Market, as it encompasses the most common form of ASD.
Roche, Novartis, Pfizer, Johnson & Johnson, GlaxoSmithKline, Merck & Co., Sanofi, AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Curemark, Consern Pharma, NeuroNascent, Alcobra Ltd., Neuropharm, Confluence Pharmaceuticals, Yamo Pharmaceuticals, Neurotrope, and Vanda Pharmaceuticals.
Autism Spectrum Disorder Market Expected to Achieve US$ 15.7 Bn by 2031 exhibiting a robust CAGR 12.3% during the forecast period.
The key drivers of the Autism Spectrum Disorder Market include rising prevalence of ASD, increasing awareness and screening, government support and funding, demand for effective therapies, advancements in diagnostics and treatment, and growing healthcare expenditure.